Loading…
Themis Medicare (THEMISMED)₹101.58+0.99%Pharmaceuticals
Themis Medicare is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 23.5 against a peer median of 50.4, and ROCE of 3.0% against a peer median of 13.9%, and latest-quarter sales growth of −11.1% against a peer median of 5.3%. By market cap it is #6 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bafna Pharmaceuticals | 1,121 | 100.0 | 11.9 | 12.4 | 0.39 | 0.0 | 150 | 11 | 8.1 | 109.1 | vs THEMISMED |
| Bajaj Healthcare | 1,062 | 54.5 | 10.9 | 9.4 | 0.47 | 0.5 | 608 | 16 | 11.5 | 16.5 | vs THEMISMED |
| Lincoln Pharmaceuticals | 1,043 | 10.8 | 16.0 | 12.0 | 0.01 | 0.3 | 672 | 88 | 17.3 | 0.0 | vs THEMISMED |
| Sigachi Industries | 1,036 | 38.2 | 6.0 | 5.8 | 0.27 | 0.4 | 478 | −83 | −5.4 | — | vs THEMISMED |
| Remus Pharmaceuticals | 968 | 26.2 | 17.1 | 12.3 | 0.08 | 0.1 | 853 | 46 | 30.2 | 19.1 | vs THEMISMED |
| Themis Medicare | 939 | 23.5 | 3.0 | 0.4 | 0.25 | 0.5 | 342 | 1 | −11.1 | — | — |
| Shree Ganesh Remedies | 861 | 71.6 | 13.9 | 10.8 | 0.16 | 0.0 | 109 | 18 | −23.2 | −67.0 | vs THEMISMED |
| Anuh Pharma | 828 | 18.6 | 15.1 | 10.7 | 0.00 | 1.8 | 776 | 41 | 4.3 | 37.6 | vs THEMISMED |
| Aptus Pharma | 811 | 175.8 | 30.0 | 30.5 | 0.31 | 0.0 | 46 | 5 | 117.3 | 60.0 | vs THEMISMED |
| Amanta Healthcare | 784 | 54.2 | 12.0 | 10.4 | 1.12 | 0.0 | 289 | 15 | 5.3 | −5.7 | vs THEMISMED |
| Shree Ganesh Remedies | 779 | 50.4 | 14.0 | 10.9 | 0.19 | 0.0 | 109 | 18 | −41.8 | −67.3 | vs THEMISMED |
| Peer median | 939 | 50.4 | 13.9 | 10.8 | 0.25 | 0.1 | 342 | 16 | 5.3 | 16.5 |
Listed companies closest to Themis Medicare in Pharmaceuticals include Bafna Pharmaceuticals, Bajaj Healthcare, Lincoln Pharmaceuticals, Sigachi Industries, Remus Pharmaceuticals, Shree Ganesh Remedies, Anuh Pharma, Aptus Pharma.
Bafna Pharmaceuticals, with a market cap of ₹1,121 Cr.
Themis Medicare trades at a P/E of 23.5; the median of its peer set is 50.4. A P/E above or below the median is a description, not a judgement on value.
Themis Medicare's return on capital employed is 3.0%, below the peer median of 13.9%.